Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyQvia Safety and Immunogenicity in Pediatric PIDD
NCT03116347Phase 4Completed
- Sponsor
- Takeda
- Start
- May 2017
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 4 trial of Human normal immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Takeda. Started May 2017; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT03116347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116347.